HMPV in Focus: Emerging Insights into a Silent Respiratory Threat

Human Metapneumovirus (HMPV) is a major cause of respiratory illness, primarily affecting young children, and can also cause severe disease in elderly or immunocompromised adults. Although first identified in 2001, retrospective studies suggest HMPV has been circulating since at least 1958, with its late discovery attributed to challenges in culturing the virus. HMPV is closely related to avian pneumovirus, indicating a possible evolutionary link, and belongs to the Metapneumovirus genus, which includes Respiratory Syncytial Virus (RSV). Both viruses cause similar respiratory conditions, making clinical differentiation difficult. HMPV infections lead to bronchiolitis, pneumonia, and other respiratory symptoms, particularly in children. Diagnosis is typically made through PCR or viral culture, as symptoms alone are insufficient for distinguishing HMPV from RSV. There is no specific antiviral treatment for HMPV; management focuses on supportive care, including oxygen therapy and hydration in severe cases. Preventative strategies include good hygiene practices and monoclonal antibody therapy for high-risk individuals. Understanding the etiology, diagnosis, and treatment of HMPV is crucial for addressing its impact on public health, especially in vulnerable populations.

Human Metapneumovirus (HMPV) is a major contributor to acute respiratory infections, particularly in young children. While it was officially identified in 2001, evidence suggests it has been circulating in human populations since at least the late 1950s. The delay in its discovery was primarily due to the challenges of culturing the virus in the lab-HMPV grows slowly and requires trypsin for optimal replication in cell cultures. These obstacles limited early research until advancements in virological techniques allowed for its proper detection.

HMPV shows significant genetic and structural similarities to avian metapneumovirus, which causes respiratory infections in birds such as turkeys. This resemblance suggests a possible evolutionary connection between the two viruses. Within the Metapneumovirus genus, only HMPV and Respiratory Syncytial Virus (RSV) are known to infect humans, both leading to respiratory illnesses. HMPV is a common cause of bronchiolitis and pneumonia in children, and its clinical presentation is often indistinguishable from RSV, complicating diagnosis without laboratory testing.

While children are the most affected group, HMPV can also cause severe respiratory illness in adults, especially older individuals and those with weakened immune systems. Infections in these vulnerable populations tend to be more severe, sometimes requiring hospitalization. Due to its significant impact on public health across different age groups, HMPV remains an important area of study in virology and infectious disease research [1,2].

Etiology

HMPV is an enveloped RNA virus containing a single-stranded, negative-sense, non-segmented genome. Initially grouped within the Paramyxoviridae family, it was reclassified in 2016 to the Pneumoviridae family under the Metapneumovirus genus. Transmission occurs mainly via respiratory droplets from infected individuals, with additional spread possible through contact with contaminated surfaces.

High-risk groups for severe HMPV infection include premature infants, immunocompromised individuals, and patients with chronic respiratory (such as COPD or asthma), cardiovascular, or neurological conditions. These underlying health issues can exacerbate the severity of the illness, sometimes leading to complications requiring hospitalization and intensive care. Due to its significant burden on public health, continued research and the development of effective prevention strategies remain essential [3-6].

Epidemiology

First discovered in Dutch children with respiratory illness in 2001, HMPV has since been recognized as a long-standing human pathogen, with antibody studies indicating its circulation since the late 1950s. This virus demonstrates a worldwide distribution with year-round transmission, though in temperate regions it shows distinct seasonal activity peaking in late winter and early spring. Genetic analysis has identified four HMPV subgroups (A1, A2, B1, and B2), all of which appear to cause similar disease severity without any particular strain showing consistent dominance [1].

The pediatric population bears the greatest disease burden, with peak susceptibility occurring before age two (average age of first infection: 22 months). Serological data indicate universal exposure by childhood's end, with 90-100% of children developing antibodies by age 5-10 years. As a major contributor to pediatric respiratory disease, HMPV causes 5-10% of hospital admissions for acute lower respiratory infections in children. The youngest infants (<6 months) face particularly high risk, demonstrating hospitalization rates triple those of children aged 6 months to 5 years [7].

Notably, HMPV demonstrates a pattern of recurrent infections throughout life. This may result from either exposure to antigenically distinct strains or incomplete protective immunity following natural infection. While healthy adults typically develop only mild upper respiratory symptoms, vulnerable populations - including elderly individuals, immunocompromised patients, and those with pre-existing pulmonary conditions - may experience severe, potentially life-threatening complications [3,4,8,9].

Pathophysiology

HMPV spreads primarily through respiratory droplets when infected individuals cough or sneeze. Following exposure, the virus typically incubates for 3-5 days before symptoms appear, though this period may vary. Infection begins when viral particles colonize the nasopharyngeal mucosa, subsequently migrating to the lower respiratory tract. The viral genome contains eight genes that generate nine proteins crucial for host cell invasion. Among these, two structural proteins - the attachment glycoprotein (G) and fusion glycoprotein (F) - are particularly important for pathogenesis. The F protein specifically interacts with host cell integrins, facilitating viral entry through membrane fusion. After penetration, the viral genetic material is released into the host cell cytoplasm, initiating replication.

The host immune system responds to HMPV infection by producing an array of inflammatory mediators, including IL-6, IFN-alpha, TNF-alpha, IL-2, and macrophage inflammatory proteins. These signaling molecules promote immune cell migration, resulting in characteristic peribronchiolar and perivascular infiltration. The inflammatory cascade involves monocyte and lymphocyte recruitment to airway tissues, creating localized inflammation. These pathological changes underlie the typical clinical presentation of HMPV infection, which includes respiratory manifestations such as productive cough, fever, mucus hypersecretion, and breathing difficulties (dyspnea). The severity of symptoms often correlates with the extent of pulmonary inflammation.

Key features of HMPV pathogenesis:

• Respiratory droplet transmission with 3- 5 day incubation
• Initial nasopharyngeal infection progressing to lower airways
• Viral entry mediated by F glycoprotein-integrin interaction
• Robust cytokine/chemokine response (IL-6, TNF-α, etc.)
• Inflammatory cell infiltration causing airway obstruction
• Characteristic respiratory symptom constellation

This complex interplay between viral replication and host immune response determines both disease presentation and clinical outcomes in infected individuals [10].

In young children, HMPV and Respiratory Syncytial Virus (RSV) infections produce nearly identical symptoms, often leading to diagnoses of pneumonia, bronchiolitis, or bronchitis. Common clinical features include fever, cough, wheezing, hypoxia, and concurrent upper and lower respiratory tract involvement [4,11]. While fever typically persists for about 10 days in hMPV-infected children, its intensity may fluctuate throughout the illness. Wheezing is particularly prominent in pediatric cases of HMPV-associated lower respiratory tract infections [12].

Although fever is uncommon in HMPV-infected adults, reinfected individuals may exhibit mild cold- or flu-like symptoms. Most cases present as self-limiting upper respiratory infections (rhino-pharyngo-laryngitis), resolving within a week. The most frequent symptoms include cough (90% of cases), rhinitis with nasal congestion and discharge (70%), and hoarseness (50-67%). Notably, while fever occurs in only 4% of adults, it affects 50–80% of pediatric cases [13,14].

Older adults with HMPV reinfections face an elevated risk of severe complications, including pneumonitis and fatal outcomes [15]. Emerging research also suggests a potential link between pediatric HMPV infections and central nervous system disorders, such as encephalitis and febrile seizures [16].

Accurate diagnosis based solely on clinical presentation remains challenging, as HMPV symptoms overlap with those of other respiratory viruses. The pathogen can cause a wide range of infections, from upper respiratory conditions (rhinitis, pharyngitis, otitis media, conjunctivitis) to lower respiratory diseases (pneumonia, bronchiolitis) [17]. Additional high-risk groups include pregnant individuals, who may experience severe complications [18], and lung transplant recipients, in whom HMPV infection can contribute to chronic allograft dysfunction [19].

In vitro studies demonstrate that HMPV produces characteristic cytopathic effects in cell culture, though these develop slowly and may include syncytia formation, cell rounding, and detachment from the culture surface. The virus's sluggish replication kinetics necessitate combining traditional culture methods with ancillary techniques for optimal detection. Immunological methods such as direct fluorescent antibody testing and ELISA, which employ HMPV-specific antibodies to identify viral antigens, significantly improve diagnostic sensitivity compared to relying solely on cytopathic observation [20].

Modern diagnostic practices have shifted from cell culture to molecular methods, with RT-PCR and real-time RT-PCR emerging as gold standards. Recent advances include the development of multiplex PCR assays capable of simultaneously detecting hMPV alongside other respiratory pathogens, offering more comprehensive diagnostic capabilities [21,22]. However, many clinical laboratories still lack access to standard RT-PCR testing for hMPV. Current protocols typically employ direct fluorescent antibody testing and immunofluorescence as first-line methods, reserving RT-PCR for confirmation of negative specimens [23].

The clinical diagnosis of HMPV remains challenging due to its nonspecific presentation that mimics other respiratory viral infections. While conventional techniques like viral culture and immunofluorescence retain some utility, their limited sensitivity renders them inferior to molecular methods. PCR-based testing has emerged as the most reliable diagnostic modality, offering superior sensitivity and specificity for definitive HMPV identification [15,24].

In cases where neurological involvement is suspected, brain MRI may reveal multiple cortical and subcortical lesions suggestive of HMPV-associated encephalitis. Cerebrospinal fluid analysis with PCR has successfully identified viral presence in some reported cases, providing definitive diagnostic confirmation [25].

Current clinical practice emphasizes supportive care as the mainstay of HMPV treatment, though several investigational therapies show potential. Experimental approaches under investigation include ribavirin, intravenous immunoglobulins, fusion inhibitors, and RNA interference technologies (siRNAs) [26-32]. While ribavirin demonstrates in vitro antiviral activity against HMPV through its guanosine analog structure that disrupts viral transcription, its clinical efficacy remains uncertain. The drug may also modulate host immune responses, further complicating its therapeutic profile [33].

For severely immunocompromised patients (e.g., transplant recipients or oncology patients), combination therapy with ribavirin and immunoglobulins may be considered as a last resort, despite inconsistent evidence regarding outcomes. Such decisions require careful risk-benefit analysis and shared decision-making between clinicians and patients [34,35]. Promisingly, the engineered monoclonal antibody mAb 338, which targets the HMPV fusion protein, has shown effectiveness in animal studies [36].

Anti-inflammatory corticosteroids have been used empirically in some cases, though robust clinical data supporting their efficacy are lacking [15,37]. Supportive measures remain fundamental, including antipyretics (acetaminophen/ibuprofen) for fever management and IV rehydration when oral intake is inadequate [38,39]. Severe respiratory cases, particularly in high-risk patients, may require advanced oxygen support, including mechanical ventilation. Fortunately, most patients achieve full recovery with appropriate care. Infection control measures should include droplet precautions, and vaccine development remains an unmet need [40].

Effective prevention of Human Metapneumovirus (HMPV) transmission relies on rigorous hand hygiene, droplet precautions, and minimizing direct contact with infected individuals. To reduce the risk of severe co-infections, HMPV-positive patients should be isolated from those with Respiratory Syncytial Virus (RSV) in healthcare settings. Special care should be taken to limit exposure to immunocompromised individuals, as HMPV-infected patients may continue shedding the virus for extended periods-ranging from days to weeks-during both active illness and early recovery [41].

Emerging evidence suggests that vaccination may play a role in mitigating HMPV-related complications. The nine-valent Pneumococcal Conjugate Vaccine (PCV9) has been associated with decreased hospitalization rates and reduced severity of HMPV illness, particularly in vulnerable pediatric populations such as children with HIV [42].

The clinical presentation of Human Metapneumovirus (HMPV) infection often resembles various other respiratory conditions, necessitating comprehensive diagnostic evaluation. Non-infectious respiratory disorders, including acute asthma attacks and COPD exacerbations, can produce symptoms nearly identical to HMPV infection. The differential diagnosis should also include bacterial pneumonia, which shares many clinical features with severe HMPV cases.

Furthermore, HMPV infection must be distinguished from other viral respiratory pathogens, particularly:

• Coronaviruses (including seasonal varieties and SARS-CoV-2)
• Rhinovirus
• Adenovirus
• Parainfluenza viruses
• Respiratory syncytial virus (RSV)
• Influenza viruses (types A and B)

Accurate diagnosis requires careful clinical assessment combined with appropriate laboratory testing to differentiate between these potentially overlapping conditions [43].

Most patients with Human Metapneumovirus (HMPV) infection experience complete recovery with supportive care, demonstrating an overall positive prognosis. However, healthcare providers should conduct thorough evaluations of comorbid conditions and vigilantly monitor for clinical indicators of severe disease progression, including:

• Respiratory distress (dyspnea)
• Oxygen desaturation (hypoxia)
• Increased work of breathing evidenced by accessory muscle use

Notably, natural infection does not confer long-term immunity, leaving individuals susceptible to recurrent HMPV infections due to the transient and partial protective immune response generated following initial exposure [43].

Human Metapneumovirus (HMPV) poses significant risks for immunocompromised individuals and those with pre-existing cardiopulmonary conditions, often resulting in serious complications requiring inpatient management. These high-risk patients frequently develop severe respiratory compromise that may progress to acute respiratory failure. Clinical management often involves escalating respiratory support, ranging from high-flow oxygen therapy to invasive mechanical ventilation in critical cases. Due to the potential for rapid clinical deterioration, such patients typically necessitate Intensive Care Unit (ICU) admission for continuous monitoring and specialized interventions [8,9].

Effective containment of Human Metapneumovirus (HMPV) requires comprehensive patient and family education regarding transmission prevention. Key preventive measures include:

• Environmental disinfection - Regular cleaning of high-touch surfaces with appropriate disinfectants
• Hand hygiene - Frequent handwashing with soap and water or alcohol-based sanitizers
• Respiratory etiquette - Implementation of droplet precautions, including proper mask usage and cough hygiene

These evidence-based interventions can significantly reduce viral transmission in both household and community settings [8].

Current research continues to evaluate novel treatment approaches for Human Metapneumovirus (HMPV). Among the most promising candidates is ribavirin, a nucleoside analog antiviral currently approved for Respiratory Syncytial Virus (RSV) management. Preliminary evidence indicates potential therapeutic benefits when combining ribavirin with Intravenous Immunoglobulin (IVIG), particularly for vulnerable populations including immunocompromised individuals and preterm neonates.

In vitro investigations demonstrate ribavirin's capacity to inhibit HMPV replication and attenuate associated pulmonary inflammation. Limited clinical data from a trial involving nine immunocompromised patients receiving combination therapy (oral/aerosolized ribavirin plus IVIG) showed partial efficacy, with two cases demonstrating positive outcomes. However, several limitations constrain widespread adoption:

• Safety concerns: Ribavirin exhibits teratogenic properties requiring strict handling protocols
• Administration challenges: Aerosolized delivery necessitates specialized equipment and trained respiratory therapists (with pregnancy contraindications)
• Economic factors: High treatment costs present accessibility barriers

These findings underscore the need for larger, controlled studies to establish definitive efficacy and safety profiles before clinical implementation [4,9].

1. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001 Jun;7(6):719-24. doi: 10.1038/89098. PMID: 11385510; PMCID: PMC7095854. 
2. Garcia–Moliner ML. Human metapneumovirus. Viruses and the lung. 2013 Aug 26;101–7. doi: 10.1007/978-3-642-40605-8_12. PMCID: PMC7122877.
3. Uche IK, Guerrero-Plata A. Interferon-Mediated Response to Human Metapneumovirus Infection. Viruses. 2018 Sep 18;10(9):505. doi: 10.3390/v10090505. PMID: 30231515; PMCID: PMC6163993.
4. Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014 Aug;25:45-52. doi: 10.1016/j.ijid.2014.03.1394. Epub 2014 May 17. PMID: 24841931; PMCID: PMC7110553.
5. Freymuth F, Vabret A, Legrand L, Dina J, Gouarin S, Cuvillon-Nimal D, Brouard J. Métapneumovirus humain [Human metapneumovirus]. Pathol Biol (Paris). 2009 Mar;57(2):133-41. French. doi: 10.1016/j.patbio.2008.04.005. Epub 2008 Jun 2. PMID: 18515017; PMCID: PMC7126272.
6. Uddin S, Thomas M. Human Metapneumovirus. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809745.
7. Inagaki A, Kitano T, Nishikawa H, Suzuki R, Onaka M, Nishiyama A, Kitagawa D, Oka M, Masuo K, Yoshida S. The Epidemiology of Admission-Requiring Pediatric Respiratory Infections in a Japanese Community Hospital Using Multiplex PCR. Jpn J Infect Dis. 2021 Jan 22;74(1):23-28. doi: 10.7883/yoken.JJID.2020.154. Epub 2020 Jun 30. PMID: 32611977.
8. Vinci A, Lee PJ, Krilov LR. Human Metapneumovirus Infection. Pediatr Rev. 2018 Dec;39(12):623-624. doi: 10.1542/pir.2017-0213. PMID: 30504257.
9. Haas L, Thijsen S, Van Elden L, Heemstra K. Human metapneumovirus in adults. Viruses. 2013;5(1):87-110. doi: 10.3390/v5010087.
10. Holzemer NF, Hasvold JJ, Pohl KJ, Ashbrook MJ, Meert KL, Quasney MW. Human Metapneumovirus Infection in Hospitalized Children. Respir Care. 2020 May;65(5):650-657. doi: 10.4187/respcare.07156. Epub 2020 Feb 11. PMID: 32047124.
11. Williams JV, Crowe JE Jr, Enriquez R, Minton P, Peebles RS Jr, Hamilton RG, Higgins S, Griffin M, Hartert TV. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis. 2005 Oct 1;192(7):1149-53. doi: 10.1086/444392. Epub 2005 Aug 29. PMID: 16136455; PMCID: PMC1476781.
12. Hamelin ME, Côté S, Laforge J, Lampron N, Bourbeau J, Weiss K, Gilca R, DeSerres G, Boivin G. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis. 2005 Aug 15;41(4):498-502. doi: 10.1086/431981. Epub 2005 Jul 15. PMID: 16028158.
13. Ramakanth P, Joanna K. Human metapneumovirus infections: A comprehensive review of diagnosis and management. Current Trends in Internal Medicine. 2025;9(1). doi: 10.29011/2638-003x.100238.
14. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 2003 Mar 1;187(5):785-90. doi: 10.1086/367901. Epub 2003 Feb 24. PMID: 12599052.
15. Arnold JC, Singh KK, Milder E, Spector SA, Sawyer MH, Gavali S, Glaser C. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J. 2009 Dec;28(12):1057-60. doi: 10.1097/INF.0b013e3181acd221. PMID: 19755929.
16. Spaeder MC, Custer JW, Bembea MM, Aganga DO, Song X, Scafidi S. A multicenter outcomes analysis of children with severe viral respiratory infection due to human metapneumovirus. Pediatr Crit Care Med. 2013 Mar;14(3):268-72. doi: 10.1097/PCC.0b013e3182720fc7. PMID: 23392374.
17. Lenahan JL, Englund J, Tielsch J, Katz J, Khatry S, Leclerq SC, Kuypers J, Steinhoff MC, Chu HY. Human metapneumovirus infection in pregnant and postpartum women. Open Forum Infectious Diseases. 2015;2(suppl_1). doi: 10.1093/ofid/ofv133.402.
18. de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, Permpalung N, Kerstjens H, Alffenaar JW, Verschuuren E. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis. 2022 Jul 6;74(12):2252-2260. doi: 10.1093/cid/ciab969. PMID: 35022697; PMCID: PMC9258934.
19. Tollefson SJ, Cox RG, Williams JV. Studies of culture conditions and environmental stability of human metapneumovirus. Virus Res. 2010 Jul;151(1):54-9. doi: 10.1016/j.virusres.2010.03.018. Epub 2010 Apr 7. PMID: 20380856; PMCID: PMC2894476.
20. Bellau-Pujol S, Vabret A, Legrand L, Dina J, Gouarin S, Petitjean-Lecherbonnier J, Pozzetto B, Ginevra C, Freymuth F. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods. 2005 Jun;126(1-2):53-63. doi: 10.1016/j.jviromet.2005.01.020. PMID: 15847919; PMCID: PMC7112904.
21. Litwin CM, Bosley JG. Seasonality and prevalence of respiratory pathogens detected by multiplex PCR at a tertiary care medical center. Arch Virol. 2014 Jan;159(1):65-72. doi: 10.1007/s00705-013-1794-4. Epub 2013 Jul 24. PMID: 23881085; PMCID: PMC7086932.
22. Jokela P, Piiparinen H, Luiro K, Lappalainen M. Detection of human metapneumovirus and respiratory syncytial virus by duplex real-time RT-PCR assay in comparison with direct fluorescent assay. Clin Microbiol Infect. 2010 Oct;16(10):1568-73. doi: 10.1111/j.1469-0691.2010.03191.x. Epub 2010 Feb 11. PMID: 20156219.
23. Ma Y. Detection of humanmetapneumovirus in clinical specimens using PCR. J Clin Microbiol. 2010;48(9):3324-3329.
24. Schildgen O, Glatzel T, Geikowski T, Scheibner B, Matz B, Bindl L, Born M, Viazov S, Wilkesmann A, Knöpfle G, Roggendorf M, Simon A. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis. 2005 Mar;11(3):467-70. doi: 10.3201/eid1103.040676. PMID: 15757568; PMCID: PMC3298257.
25. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003 Sep;60(1):51-9. doi: 10.1016/s0166-3542(03)00153-0. PMID: 14516921.
26. Kitanovski L, Kopriva S, Pokorn M, Dolničar MB, Rajić V, Stefanović M, Jazbec J. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol. 2013 Oct;35(7):e311-3. doi: 10.1097/MPH.0b013e3182915d2d. PMID: 23669731.
27. Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006 Aug;80(16):7799-806. doi: 10.1128/JVI.00318-06. PMID: 16873237; PMCID: PMC1563801.
28. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013 Sep 19;501(7467):439-43. doi: 10.1038/nature12442. Epub 2013 Aug 18. PMID: 23955151.
29. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. doi: 10.1128/AAC.00793-07. Epub 2007 Oct 29. PMID: 17967906; PMCID: PMC2223880.
30. Deffrasnes C, Cavanagh MH, Goyette N, Cui K, Ge Q, Seth S, Templin MV, Quay SC, Johnson PH, Boivin G. Inhibition of human metapneumovirus replication by small interfering RNA. Antivir Ther. 2008;13(6):821-32. PMID: 18839783.
31. Darniot M, Schildgen V, Schildgen O, Sproat B, Kleines M, Ditt V, Pitoiset C, Pothier P, Manoha C. RNA interference in vitro and in vivo using DsiRNA targeting the nucleocapsid N mRNA of human metapneumovirus. Antiviral Res. 2012 Mar;93(3):364-73. doi: 10.1016/j.antiviral.2012.01.004. Epub 2012 Jan 20. PMID: 22285728.
32. Park SY, Baek S, Lee SO, Choi SH, Kim YS, Woo JH, Sung H, Kim MN, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother. 2013 Feb;57(2):983-9. doi: 10.1128/AAC.01961-12. Epub 2012 Dec 10. PMID: 23229488; PMCID: PMC3553680.
33. Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, Kwak EJ, Rinaldo CR Jr, Pilewski JM, McCurry KR, Husain S. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007 Aug;26(8):862-4. doi: 10.1016/j.healun.2007.05.020. Epub 2007 Jul 12. PMID: 17692793; PMCID: PMC7111659.
34. Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, Boivin G. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res. 2010 Oct;88(1):31-7. doi: 10.1016/j.antiviral.2010.07.001. Epub 2010 Jul 7. PMID: 20619294.
35. Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L. Antiviral strategies against human metapneumovirus: Targeting the fusion protein. Antiviral Res. 2022 Nov;207:105405. doi: 10.1016/j.antiviral.2022.105405. Epub 2022 Sep 6. PMID: 36084851.
36. González LA, Vázquez Y, Mora JE, Palavecino CE, Bertrand P, Ferrés M, Contreras AM, Beckhaus AA, Riedel CA, Bueno SM. Evaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples. J Virol Methods. 2018 Apr;254:51-64. doi: 10.1016/j.jviromet.2018.01.011. Epub 2018 Feb 1. PMID: 29410056.
37. Choi SH, Hong SB, Huh JW, Jung J, Kim MJ, Chong YP, Kim SH, Sung H, Koo HJ, Do KH, Lee SO, Lim CM, Kim YS, Woo JH, Koh Y. Outcomes of severe human metapneumovirus-associated community-acquired pneumonia in adults. J Clin Virol. 2019 Aug;117:1-4. doi: 10.1016/j.jcv.2019.05.007. Epub 2019 May 15. PMID: 31128379; PMCID: PMC7106415.
38. Velayutham TS, Ivanciuc T, Garofalo RP, Casola A. Role of human metapneumovirus glycoprotein G in modulation of immune responses. Front Immunol. 2022 Jul 25;13:962925. doi: 10.3389/fimmu.2022.962925. PMID: 35958551; PMCID: PMC9357950.
39. III. Precautions to prevent transmission of infectious agents. Infection Control. 2023.
40. Sepúlveda-Pachón IT, Dunne EM, Hanquet G, Baay M, Menon S, Jodar L, Gessner BD, Theilacker C. Effect of Pneumococcal Conjugate Vaccines on Viral Respiratory Infections: A Systematic Literature Review. J Infect Dis. 2024 Sep 23;230(3):e657-e667. doi: 10.1093/infdis/jiae125. PMID: 38462672; PMCID: PMC11420806.
41. Hermos CR, Vargas SO, McAdam AJ. Human metapneumovirus. Clin Lab Med. 2010 Mar;30(1):131-48. doi: 10.1016/j.cll.2009.10.002. PMID: 20513544; PMCID: PMC7115734.
42. Schildgen V, van den Hoogen B, Fouchier R, Tripp RA, Alvarez R, Manoha C, Williams J, Schildgen O. Human Metapneumovirus: lessons learned over the first decade. Clin Microbiol Rev. 2011 Oct;24(4):734-54. doi: 10.1128/CMR.00015-11. PMID: 21976607; PMCID: PMC3194831.
43. Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011 Jun;13(3):324-8. doi: 10.1111/j.1399-3062.2010.00575.x. Epub 2010 Oct 3. PMID: 21631655; PMCID: PMC3107511.